VANCOUVER, BC / ACCESSWIRE / September 13, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind“, the “Company“), announced it has completed the sale of assets related to its consumer division, including e-commerce operations and underlying functional food assets, as well as shares owned in Translational Life Sciences Inc. (“TLS”), for a combined consideration of…


Previous articleThe Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part 1
Next articlePerception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression